Abstract:The current drug virtual screen (VS) methods mainly include two categories. i.e., ligand/target structure-based virtual screen and that, utilizing protein-ligand interaction fingerprint information based on the large number of complex structures. Since the former one focuses on the one-side information while the later one focuses on the whole complex structure, they are thus complementary and can be boosted by each other. However, a common problem faced here is how to present a comprehensive understanding and evaluation of the various virtual screen results derived from various VS methods. Furthermore, there is still an urgent need for developing an efficient approach to fully integrate various VS methods from a comprehensive multiview perspective. In this study, our virtual screen schema based on multiview similarity integration and ranking aggregation was tested comprehensively with statistical evaluations, providing several novel and useful clues on how to perform drug VS from multiple heterogeneous data sources. (1) 18 complex structures of HIV-1 protease with ligands from the PDB were curated as a test data set and the VS was performed with five different drug representations. Ritonavir ( 1HXW ) was selected as the query in VS and the weighted ranks of the query results were aggregated from multiple views through four similarity integration approaches. (2) Further, one of the ranking aggregation methods was used to integrate the similarity ranks calculated by gene ontology (GO) fingerprint and structural fingerprint on the data set from connectivity map, and two typical HDAC and HSP90 inhibitors were chosen as the queries. The results show that rank aggregation can enhance the result of similarity searching in VS when two or more descriptions are involved and provide a more reasonable similarity rank result. Our study shows that integrated VS based on multiple data fusion can achieve a remarkable better performance compared to that from individual ones and, thus, serves as a promising way for efficient drug screening, taking advantages of the rapidly accumulated molecule representations and heterogeneous data in the pharmacological area.

VRPharmer: Bringing Virtual Reality into Pharmacophore-Based Virtual Screening with Interactive Exploration and Realistic Visualization.

Using virtual reality for drug discovery: a promising new outlet for novel leads.

ePharmer : An integrated and graphical software for pharmacophore‐based virtual screening

Quantitative Structure–activity Relationship: Promising Advances in Drug Discovery Platforms

Touching proteins with virtual bare hands: how to visualize protein-drug complexes and their dynamics in virtual reality

Interactivity: the missing link between virtual reality technology and drug discovery pipelines

An Integrated Virtual Screening Approach for VEGFR-2 Inhibitors.

An artificial intelligence accelerated virtual screening platform for drug discovery

Multiple-step Virtual Screening Using VSM-G: Overview and Validation of Fast Geometrical Matching Enrichment

Virtual Drug Screen Schema Based on Multiview Similarity Integration and Ranking Aggregation

Virtual Bio-Molecular Modeling

QSAR-Based Virtual Screening: Advances and Applications in Drug Discovery

3D-Pharma, A Ligand-based Virtual Screening tool using 3D Pharmacophore Fingerprints

VRmol: an Integrative Web-Based Virtual Reality System to Explore Macromolecular Structure

Molecular Interactions Using New Technology: A Virtual Reality Gaming Platform to Visualize and Manipulate Molecules

Virtual-Physical Interaction System

RealVS: Toward Enhancing the Precision of Top Hits in Ligand-Based Virtual Screening of Drug Leads from Large Compound Databases

Pharmit: interactive exploration of chemical space

SVSBI: Sequence-based virtual screening of biomolecular interactions

Virtual Screening on Natural Products for Discovering Active Compounds and Target Information

Receptor-based pharmacophore and pharmacophore key descriptors for virtual screening and QSAR modeling.